
Hematologic Oncology
Latest News
Advertisement
Latest Videos

CME Content
Advertisement
More News




The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.














Ruben A. Mesa, MD, discusses the significance of the RESPONSE study for patients with polycythemia vera.







Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC
2
On World Cancer Day, Northwell Highlights a Blueprint for Consistent, System-Wide Cancer Care
3
Acalabrutinib Delivers Strong Responses With Manageable Toxicities in Steroid-Refractory cGVHD
4
Enfortumab Vedotin Dose Reductions May Improve Tolerability Without Impeding OS in Advanced Urothelial Carcinoma
5













































